The effect of combination of valproic acid and anti-tumor drug on pancreatic and biliary cancer

The effect of combination of valproic acid and anti-tumor drug on pancreatic and biliary cancer - The effect of valproic acid on pancreatic and biliary cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004525

Enrollment

Registered

2010-11-15

Start date

2010-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unresectable or reccurrent pancreatic cancer and biliary cancer (20 patients)

Interventions

To administer valproic acid 15mg/kg twice a day.We estimate the blood concentration of valproic acid once a month. If the patients have the no side effects, we will continue to administer valproic aci

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) The patients informed of pancreatic cancer or biliary cancer (2) Unresectable or reccurrent patients (3) The patients taken informed consent

Exclusion criteria

Exclusion criteria: (1) The patients have severe organ disorder. (2) The patients have more than 2.5 times of AST or ALT. (3) The patients have more than 2mg/dl of Total-Bilirubin. (4) The patients have more than 5mg/dl of Creatinin. (5) The patients have less than 90% of SaO2. (6) The patients have severe organ complication. (7) The patiens have allergy. (8) The patients have agressive duplication cancer. (9) The patients is considered unaddaptive.

Design outcomes

Primary

Measure	Time frame
tumor marker and tumor size	—

Countries

Japan

Contacts

Public ContactShuichi Iwahashi

Tokushima university hospital Department of surgery

iwahashi@clin.med.tokushima-u.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026